These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26652899)

  • 21. Baseline medical comorbidities in adults randomized in the STRIDE trial for psychostimulant use disorders.
    Dela Cruz AM; Carmody T; Greer TL; Rethorst CD; Warden D; Walker R; Trivedi MH
    Am J Addict; 2016 Apr; 25(3):215-20. PubMed ID: 26991889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Examining Longitudinal Stimulant Use and Treatment Attendance as Parallel Outcomes in Two Contingency Management Randomized Clinical Trials.
    McPherson S; Brooks O; Barbosa-Leiker C; Lederhos C; Lamp A; Murphy S; Layton M; Roll J
    J Subst Abuse Treat; 2016 Feb; 61():18-25. PubMed ID: 26456717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Commentary on Konstenius et al. (2014): on medication development for stimulant addiction.
    Shoptaw S
    Addiction; 2014 Mar; 109(3):450-1. PubMed ID: 24524320
    [No Abstract]   [Full Text] [Related]  

  • 24. Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTTION systematic review and recommendations.
    Smith SM; Wang AT; Katz NP; McDermott MP; Burke LB; Coplan P; Gilron I; Hertz SH; Lin AH; Rappaport BA; Rowbotham MC; Sampaio C; Sweeney M; Turk DC; Dworkin RH
    Pain; 2013 Jul; 154(7):997-1008. PubMed ID: 23602344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.
    Kishi T; Matsuda Y; Iwata N; Correll CU
    J Clin Psychiatry; 2013 Dec; 74(12):e1169-80. PubMed ID: 24434105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents.
    Wilens TE; Adamson J; Monuteaux MC; Faraone SV; Schillinger M; Westerberg D; Biederman J
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):916-21. PubMed ID: 18838643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming cocaine or stimulant addiction. Medications offer modest help; vaccines are in development.
    Harv Ment Health Lett; 2009 Mar; 25(9):6-7. PubMed ID: 19368038
    [No Abstract]   [Full Text] [Related]  

  • 28. Adverse Event Reporting in Clinical Trials of Intravenous and Invasive Pain Treatments: An ACTTION Systematic Review.
    Williams MR; McKeown A; Pressman Z; Hunsinger M; Lee K; Coplan P; Gilron I; Katz NP; McDermott MP; Raja SN; Rappaport BA; Rowbotham MC; Turk DC; Dworkin RH; Smith SM
    J Pain; 2016 Nov; 17(11):1137-1149. PubMed ID: 27522950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of abstinence-based incentives: interaction with intake stimulant test results.
    Stitzer ML; Petry N; Peirce J; Kirby K; Killeen T; Roll J; Hamilton J; Stabile PQ; Sterling R; Brown C; Kolodner K; Li R
    J Consult Clin Psychol; 2007 Oct; 75(5):805-11. PubMed ID: 17907862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment outcomes of stimulant misusers: one year follow-up results from the national treatment outcome research study (NTORS).
    Gossop M; Marsden J; Stewart D
    Addict Behav; 2000; 25(4):509-22. PubMed ID: 10972443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human abuse liability evaluation of CNS stimulant drugs.
    Romach MK; Schoedel KA; Sellers EM
    Neuropharmacology; 2014 Dec; 87():81-90. PubMed ID: 24793872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting treatment outcome in stimulant dependence.
    Reske M; Paulus MP
    Ann N Y Acad Sci; 2008 Oct; 1141():270-83. PubMed ID: 18991963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognitive remediation in the treatment of stimulant abuse disorders: a research agenda.
    Vocci FJ
    Exp Clin Psychopharmacol; 2008 Dec; 16(6):484-97. PubMed ID: 19086769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychosocial interventions in stimulant use disorders: a focus on women.
    De Giorgi R; D'Alò GL; De Crescenzo F
    Curr Opin Psychiatry; 2017 Jul; 30(4):275-282. PubMed ID: 28441169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The development and evaluation of stimulant treatment programmes.
    Ezard N; Hodge S; Dolan K
    Curr Opin Psychiatry; 2015 Jul; 28(4):280-5. PubMed ID: 26001918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.
    Merkel RL; Kuchibhatla A
    Expert Opin Drug Saf; 2009 Nov; 8(6):655-68. PubMed ID: 19785509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of obesity for opioid- and stimulant-dependent participants in substance use treatment clinical trials.
    Hu L; Matthews A; Shmueli-Blumberg D; Killeen TK; Tai B; VanVeldhuisen P
    Drug Alcohol Depend; 2018 Sep; 190():255-262. PubMed ID: 30077926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recommendations for Clinical Trials in ICH: The Second Hemorrhagic Stroke Academia Industry Roundtable.
    ;
    Stroke; 2020 Apr; 51(4):1333-1338. PubMed ID: 32078490
    [No Abstract]   [Full Text] [Related]  

  • 40. Impact of stimulant pharmacotherapy on sleep quality: post hoc analyses of 2 large, double-blind, randomized, placebo-controlled trials.
    Surman CB; Roth T
    J Clin Psychiatry; 2011 Jul; 72(7):903-8. PubMed ID: 21824454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.